The metabolic syndrome as factor of additional cardio vascular risk under ischemic heart disease


Cite item

Full Text

Abstract

The sampling of 331 patients with ischemic heart disease was included in the study to evaluate biochemical, immunologic indicators of blood, affective condition. The analysis of blood serum of patients with ischemic heart disease revealed presence of increased levels of total cholesterol, triglycerides, leptin, insulin, HOMA-IR index, total oxidizing ability of blood, oxidized low-density lipoproteins, proinflammatory cytokines interleukins-1, interleukins-6, tumor necrosis factor, adrenocorticotrophic hormone, cortisol, lowered content of total cholesterol high-density lipoproteins, total antioxidant activity of blood, superoxiddismutase. Also, increased level of depression was established, especially expressed in case of presence of concomitant metabolic syndrome.

About the authors

Aleksandr V. Dontsov

The N.N. Burdenko Voronezhskiy state medical university of Minzdrav of Russia

Email: ledn89@mail.ru
candidate of medical sciences, assistant professor of the chair of propaedeutics of internal diseases «Voronezh state medical university N.N. Burdenko» 394036, Voronezh, Russia

References

  1. Национальные рекомендации по диагностике и лечению метаболического синдрома: второй пересмотр. М.; 2009.
  2. Кобалава Ж.Д. Субклиническое воспаление и окислительный статус у больных с нелеченым сахарным диабетом 2-го типа. Артериальная гипертензия. 2008; 14 (2): 151-61.
  3. Звенигородская Л.А. Эволюция представлений о метаболическом синдроме. Экспериментальная и клиническая гастроэнтерология. 2010; (7): 3-5.
  4. Беляева И.Г., Смакаева Э.Р., Грицаенко Г.А., Мингазетдинова Л.Н. Кардиометаболический синдром как предиктор течения артериальной гипертонии. Российский кардиологический журнал. 2011; (4): 19-22.
  5. Щеплягина Л.А. Лептин и его роль в организме. Российский педиатрический журнал. 2005; (4): 33-6.
  6. Кучер А.Г. Лептин - новый гормон жировой ткани: значение в развитии ожирения, патологии сердечно-сосудистой системы и почек. Нефрология. 2005; 9 (1): 9-19.
  7. Мамедов М.Н. Метаболический синдром: практические аспекты диагностики и лечения в амбулаторных условиях. М.: ФАСмедиа; 2005.
  8. Гуревич В.С. Современные представления о патогенезе атеросклероза. Болезни сердца и сосудов. 2006; 1 (4): 126-34.
  9. Погосова Г.В. Депрессия - новый фактор риска ишемической болезни сердца и предиктор коронарной смерти. Кардиология. 2002; 42 (4): 86-90.
  10. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24 (4): 683-9.
  11. Stelzer I., Zelzer S., Raggam R.B., Prüller F., Truschnig-Wilders M., Meinitzer A. et al. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl. Res. 2012; 159 (2): 118-24.
  12. Mathieu P. Visceral obesity and the heart. Int. J. Biochem. Cell Biol. 2008; 40 (5): 821-36.
  13. Colas R., Sassolas A., Guichardant M., Cugnet-Anceau C., Moret M., Moulin P. et al. LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia. 2011; 54 (11): 2931-40.
  14. Andrew M.E., McCanlies E.C., Burchfi el C.M., Charles L.E., Hartley T.A., Fekedulegn D. et al. Hardiness and psychological distress in a cohort of police officers. Int. J. Emerg. Mental Health. 2008; 10 (2): 137-47.
  15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment (HOMA): insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28 (7): 412-9.
  16. Zung W.W. A self-rating depression scale. Arch. Gen. Psychiatry. 1965; 12: 63-70.
  17. Mattson M.P. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp. Gerontol. 2009; 44 (10): 625-33.
  18. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998; 83 (3): 847-50.
  19. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107 (3): 363-9.
  20. Anagnostis P. Metabolic syndrome in the Mediterranean region: Current status. Indian J. Endocrinol. Metab. 2012; 16 (1): 72-80.
  21. Matthews K., Schwartz J., Cohen S., Seeman T. Diurnal cortisol decline is related to coronary calcification: CARDIA study. Psychosom. Med. 2006; 68 (5): 657-61.
  22. Ayari H. Respective roles of cortisol, aldosterone and angiotensin II during pathophysiology of atherosclerosis. Ann. Biol. Clin. (Paris). 2013; 71 (4): 381-8.
  23. Fruehwald-Schultes B., Kern W., Bong W., Wellhoener P., Kerner W., Born J. et al. Supraphysiological hyperinsulinemia acutely increases hypothalamic-pituitary-adrenal secretory activity in humans. J. Clin. Endocrinol. Metab. 1999; 84 (9): 3041-6.
  24. Rosmond R., Björntorp P. The The association between C-reactive protein levels and depression: results from the hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J. Intern. Med. 2000; 247 (2): 188-97.
  25. Liukkonen T., Silvennoinen-Kassinen S., Jokelainen J., Räsänen P., Leinonen M., Meyer-Rochow V.B. et al. The association between C-reactive protein levels and depression: Results from the northern Finland 1966 birth cohort study. Biol. Psychiatry. 2006; 60 (8): 825-30.
  26. Capuron L., Su S., Miller A.H., Bremner J.D., Goldberg J., Vogt G.J. et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link. Biol. Psychiatry. 2008; 64 (10): 896-900.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies